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Aim To evaluate (I) trastuzumab-containing primary systemic 
therapy (PST) in human epidermal growth factor receptor 2 
(Her2) overexpressing breast carcinomas.; (II) compare the pa-
tients who achieved and those who did not achieve pathologi-
cal complete remission (pCR), and (III) analyze the accuracy of 
different clinical-imaging modalities in tumor response moni-
toring.
Methods 188 patients who received PST between 2008 and 
2014 were reviewed and 43 Her2 overexpressing breast can-
cer patients (28 Luminal B/Her2-positive and 15 Her2-positive) 
were enrolled. 26 patients received mostly taxane-based PST 
without trastuzumab (Group 1) and 17 patients received tras-
tuzumab-containing PST (Group 2). We compared the con-
cordance between pCR and complete remission (CR) defined 
by breast-ultrasound, CR defined by standard 18F-fluoro-de-
oxy-glucose positron emission tomography and computer-
ized tomography (FDG-PET/CT) criteria (Method 1) and CR 
defined by a novel, breast cancer specific FDG-PET/CT criteria 
(Method 2). Sensitivity (sens), specificity (spec), and positive 
(PPV) and negative predictive values (NPV) were calculated.
Results Ten patients (38.5%) in Group 1 and eight (47%) in 
Group 2 achieved pCR. pCR was significantly more frequent in 
Her2-positive than in Luminal B/Her2-positive tumors in both 
Group 1: (P = 0.043) and Group 2: (P = 0.029). PET/CT evaluated 
by the breast cancer specific criteria (Method 2) differentiated 
pCR from non-pCR more accurately in both groups (Group 
1: sens = 77.8%, spec = 100%, PPV = 100%, NPV = 71.4%; Group 
2: sens = 87.5%, spec = 62.5%, PPV = 70%, NPV = 83.3%) than 
standard PET/CT criteria (Method 1) (Group 1: sens = 22.2% 
spec = 100% PPV = 100% NPV = 41.7%; in Group 2: sens = 37.5%, 
spec = 87.5%, PPV = 75% NPV = 58.3%) or breast ultrasound 
(Group 1, sens = 83.3% spec = 25% PPV = 62.5% NPV = 50%; 
Group 2, sens = 100% spec = 12.5% PPV = 41.6% NPV = 100%).
Conclusion The benefit of targeted treatment with trastu-
zumab-containing PST in Her2 overexpressing breast cancer 
was defined in terms of pCR rate. Luminal B/Her2-positive 
subtype needs further subdivision to identify patients who 
would benefit from PST. Combined evaluation of tumor re-
sponse by our novel, breast cancer specific FDG-PET/CT crite-
ria accurately differentiated pCR from non-pCR patients.
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The initial main goal of primary systemic therapy (PST, 
also known as neoadjuvant therapy) was to allow surgi-
cal intervention in locally advanced breast cancer and 
inflammatory breast cancer by downstaging (1-5). How-
ever, it led to favorable clinical response rates (reach-
ing 65%) and pathological complete remission (pCR) 
rates (between 4%-29%) (6), and patients achieving pCR 
showed significantly longer disease-free and overall sur-
vival than non-responders (7-9). Based on these results, 
achievement of pCR became the primary endpoint of 
PST. Moreover, introduction of trastuzumab, the first tar-
geted agent against human epidermal growth factor re-
ceptor 2 (Her2), in the PST setting improved the pCR rate 
and resulted in longer disease-free survival in Her2 over-
expressing breast cancers (10,11).
In Hungary, trastuzumab-containing PST for Her2 overex-
pressing breast cancers has been routinely available since 
2013. The aims of our study are:
(I) to evaluate the benefit of personalized, trastuzumab-
containing PST regimens in daily routine practice com-
pared to treatments without this agent.
(II) to compare patients who after the therapy (with or 
without trastuzumab) achieved pCR and those who did 
not (non-pCR ~ any form of residual disease after PST).
(III) to compare the accuracy of clinical-imaging tests to as-
sess tumor response after PST by using breast ultrasound 
and fluoro-deoxy-glucose positron emission tomography 
and computerized tomography (FDG-PET/CT).
Our third hypothesis is based on the fact that initiating 
a personalized and targeted treatment approach calls for 
accurate monitoring of treatment response. By using re-
liable predictive factors for tumor response, oncologists 
will be able to adapt and modify therapeutic regimens 
during PST to achieve pCR more frequently and improve 
clinical outcomes (1-4). At first, upon administration of PST 
for breast cancer, local extension of the tumor and ther-
apeutic response were measured routinely with conven-
tional imaging techniques like breast ultrasound (2). Over 
the past decade FDG-PET/CT imaging proved suitable for 
breast cancer staging as well as for response evaluation 
during PST (12-14). However, only a limited number of 
studies are available on the application of FDG-PET/CT in 
Her2 overexpressing breast carcinomas and its accuracy is 
questionable when targeted, biological therapies are ad-
ministered (15-21).
To improve the accuracy of end-therapy imaging, we 
evaluated the FDG-PET/CT scans not just by standard me-
tabolism-based criteria but also by a novel, combined im-
aging analysis method. In the case of breast malignancy 
there are no specific response criteria to assess the tumor 
response to PST besides the standard generalized PET Re-
sponse Criteria in Solid Tumors (PERCIST) criteria (22). In 
PERCIST, morphology is considered as relevant in case of 
disease progression, but not if complete remission (CR) is 
evaluated. We wanted to develop an evaluation method 
that combined the metabolism and morphology-based 
tumor response criteria to define CR, but in a more sim-
plified and less time-consuming manner. We compared 
the applicability of the standard and novel methods in 
Her2 overexpressing tumors treated with standard che-
motherapy as well as with targeted, trastuzumab-con-
taining PST.
PATienTS AnD MeThoDS
Patients
Patients diagnosed with primary breast cancer and treated 
with PST at the Oncological Division of the 1st Department 
of Internal Medicine of the Semmelweis University be-
tween 2008 and 2014 were retrospectively identified. The 
FiGure 1. Study flow-chart showing the number of patients 
with her2 overexpressing tumors (her2+) among those receiv-
ing primary systemic therapy (PST). *reason for exclusion: PST 
was not completed.
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diagnosis of breast cancer was confirmed by core biopsy. 
After completion of PST, all patients underwent surgery. 
Ethical approval for the study was given by Semmelweis 
University Institutional Review Board and written informed 
consent was waived (SE. TUKEB 120/2013).
histopathological analysis and pathological response 
evaluation
Histological analysis of tumor tissues was performed rou-
tinely on core biopsy specimens before therapy and on 
surgical samples after the PST. On core biopsy samples, 
detailed histological characterization was performed 
(histological type, nuclear grade, tubule formation, mi-
totic index, inflammatory cell infiltrate, presence or ab-
sence of in situ carcinoma component and lymphovas-
cular invasion). On surgical samples, pCR was diagnosed 
only if no viable invasive tumor cells were identified af-
ter the whole tumor bed was embedded and thoroughly 
investigated. If residual tumor was present, the detailed 
histological characterization was repeated and tumor 
size and nodal stage were assessed. Immunohistochem-
istry (IHC) was performed on paraffin-embedded tissue 
samples to evaluate hormone receptor (HR) (estrogen or 
progesterone), Her2 expression, Ki-67 labeling index (Ki-
67 LI), and p53 tumor suppressor protein. HR positivity 
was confirmed if the Allred score was above or equal to 3 
(23). Only Her2 positive patients were included in the cur-
rent analysis (Figure 1). Her2 overexpression was defined 
as IHC 3+. For IHC 2+ samples, fluorescent in situ hybrid-
ization (FISH) was performed to confirm gene amplifica-
tion. Her2 1+ or 0 tumors were considered as Her2 nega-
tive and were excluded from the analysis. Her2 status was 
defined according to the ASCO/CAP Guideline valid at 
the time of diagnosis, ie, Her2-positive patients treated 
between 2008 and November 2013 were identified ac-
cording to the 2007 ASCO/CAP Guideline (24), and from 
then on according to the Guideline published in October 
2013 (25).
Biological subtypes of tumors were defined according to 
the recommendations of the 13th St. Gallen Internation-
al Breast Cancer Conference (26) as follows: Luminal B-like 
Her2 positive tumors (Luminal B/Her2-positive) were de-
fined by immunohistochemistry as both Her2 and HR posi-
tive and Her2-positive subtypes were defined as Her2 posi-
tive and HR negative.
Patients who achieved pCR were identified according 
to national consensus recommendations (23) based 
on the Pinder response classification (27). Briefly, the defi-
nition of pCR was the following: no residual tumor tissue in 
the surgical samples, but presence of ductal carcinoma in 
situ was allowed.
Clinical response evaluation
For local staging of primary tumors, physical examina-
tion, breast ultrasound, and x-ray mammography were 
performed. To evaluate the presence of distant metasta-
ses, FDG-PET/CT scans were performed. If PET/CT was not 
available or applicable, chest, abdominal, and pelvic CT 
with bone scintigraphy was chosen for staging. Clinical 
TNM stage was determined according to the 7th edition 
of American Joint Committee on Cancer classification (5). 
After PST, the tumor response of primary breast lesions was 
evaluated by PET/CT (if PET/CT was used for staging) or by 
ultrasound alone.
ultrasound evaluation
Breast ultrasound (Esaote MyLab TM 25, Esaote North 
America, Indianapolis, IN, USA; Philips HD 15TM, Philips 
Healthcare, Andover, MA, USA) was performed routinely 
before and after PST by two experienced breast-radiol-
ogists. The same radiologist performed all the tests for 
the same patient to avoid inter-observer variability and 
consequential bias; otherwise ultrasound results were ex-
cluded from the analysis. Target breast lesions (longest di-
ameter) were measured in every session. CR was defined 
as no sign of residual tumor tissue by ultrasound after the 
last cycle of PST.
PeT/CT response
PET/CT scans were performed with dedicated whole-body 
PET/CT scanners (Siemens BiographTM TruePointTM HD, Sie-
mens Healthcare, Malvern, PA, USA; GE DiscoveryTM ST 8, 
GE Healthcare, Waukesha, WI, USA) following standard pro-
tocols and guidelines to ensure the highest reproducibil-
ity and comparability (22,28-30). The author who analyzed 
PET/CT images was blinded to the patient’s clinical records 
(results of conventional imaging). The regions of interests 
were located manually over the primary tumor (31,32). Two 
types of response evaluations were performed:
(1) Method 1: On FDG-PET/CT scans, maximum of the 
Standardized Uptake Value (SUVmax) was measured. 
Based on SUVmax (weights of patients were relatively 
stable during the study period), PERCIST criteria were ap-
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plied to define CR. The PERCIST-based definition of com-
plete remission is the following: complete resolution of 
18F-FDG uptake within measurable target lesion with the 
disappearance of all other lesions to background blood-
pool levels and without new 18F-FDG-avid lesions in pat-
tern typical of cancer. In the PERCIST-defined CR criteria, 
Response Evaluation Criteria in Solid Tumors (RECIST)-
based evaluation of tumor morphology is only consid-
ered in the case of progression (22). In our study, cases 
with partial remission, stable disease, or tumor progres-
sion were simply categorized as tumors with non-com-
plete remission (non-CR).
(2) Method 2: Additional, novel evaluation of PET/CT ex-
aminations was performed. Morphological tumor remis-
sion was defined according to RECIST (Response Evalua-
tion Criteria in Solid Tumors, v1.1) for CT (33). All primary 
breast lesions were initially measurable on CT by RECIST 
and were suitable for response evaluation by this method. 
CR was defined as both metabolic (CR defined by PERCIST) 
and morphological (CR defined by RECIST) CR. If either cri-
terion (PERCIST or RECIST) showed residual disease (ie, par-
tial remission, stable disease, or progression), the response 
could not be classified as CR.
Correlation with pathological response
The breast ultrasound-based and the PET/CT-based CR rates 
– defined by Method 1 and Method 2 – were compared with 
the pCR rates after the PST to assess the accuracy of the ap-
plied imaging modalities and response evaluation methods.
Statistical analysis
Data are expressed as mean ± standard deviation (SD). 
Mann-Whitney tests were used to compare response 
evaluation markers and tumor characteristics of pCR 
and non-pCR groups. For binomial data, contin-
Characteristics no. Percent
Age
<30 years  2   4.6
30–39 years  3   7
40–49 years 12  28
50–59 years 17  39.5
≥60 years  9  20.9
Menopausal status
premenopausal 18  41.9
perimenopausal 23  53.5
postmenopausal  2   4.6
Clinical T stage
T1c  4   9.3
T2 28  65.1
T3  5  11.6
T4  6  14
Clinical n stage
N0 19  44.2
N1 18  41.9
N2  2   4.6
N3  4   9.3
histology
invasive ductal carcinoma 37  86.1
invasive lobular carcinoma  2   4.6
other  4   9.3
Grade†
2 13  30.2
3 28  65.1
Biological subtype
Her2-positive 15  34.9
Luminal B/Her2-positive 28  65.1
Estrogen receptor status
positive 27  62.8
negative 16  37.2
Progesterone receptor status
positive 25  58.1
negative 18  41.9
Her2 status
positive 43 100
Ki-67 Li‡§
high 35  81.4
low  6  13.9
p53 statusii
positive 24  55.8
Treatment regimen – Group 1 (n = 26)
docetaxel + carboplatin  9  34.6
docetaxel + epiadriamycin  6  23.1
doxorubicin + paclitaxel  3  11.5
5-fluorouracil + epirubicin + cyclophosphamide  2   7.7
docetaxel + doxorubicin + cyclophosphamid  6  23.1
Characteristics no. Percent
Treatment regimen – Group 2 (n = 17)
trastuzumab + Docetaxel 4x → FEC 4x  9  53
trastuzumab + Docetaxel + carboplatin  4  23.5
trastuzumab + Docetaxel  4  23.5
*FeC – 5-fluorouracil + epirubicin + cyclophosphamide; her2 – human 
epidermal growth factor receptor 2; Li – labeling index.
†Grade 1: 0, unknown: 2 patients.
‡unknown: 2 patients.
§Cut-off: 14%.
iiunknown: 3 patients.
TABLe 1. Patient and tumor characteristics (n = 43)*
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gency tables were constructed and Fisher exact tests were 
applied due to the relatively low number of cases in each 
category. All applied statistical tests were two-sided, and 
P-values <0.05 were considered significant. To measure the 
accuracy of the applied clinical response criteria, we calcu-
lated sensitivity, specificity, and positive and negative pre-
dictive values of the diagnostic tests. For data collection 
and processing we used Microsoft Excel 2010 (Microsoft 
Corp, Redmond, WA, USA), Statistica 64 11 (StatSoft Inc., 
Tulsa, OK, USA) and MedCalc 13.2.2 (http://www.medcalc.
org/) software.
reSuLTS
Patient characteristics and treatment schedules
Among 188 breast cancer patients who underwent PST, 
there were 46 Her2 overexpressing tumors and 43 patients 
were enrolled in the study (Figure 1). Among the 43 patients 
(age 51.47 ± 11.07 years), 15 had Her2-positive subtype and 
28 Luminal B/Her2-positive breast cancer. All patients were 
treated with PST, most commonly in 3 week schedules, for 
6-8 cycles. 26 patients received mostly taxane-based PST 
TABLe 2. Subgroup analysis of patients who achieved pathological complete remission (pCr) and those who did not (non-pCr) in 
Group 1 and Group 2*
Group 1 Group 2
n Mean ± SD P n Mean ± SD P
histological characteristics
Ki-67 LI (%)
 pCR  9 52.7 ± 25.1 0.16 8 32.5 ± 13.7 0.45
 non-pCR 16 37.4 ± 23.6 8 29.4 ± 18.8
Grade†
 pCR‡ grade 2 = 4  grade 3 = 5 0.67 grade 2 = 0 grade 3 = 9 0.07
 non-pCR§ grade 2 = 5  grade 3 = 11 grade 2 = 4 grade 3 = 4
Subtype†
 pCR Luminal B/Her2-pos. = 3  
Her2-positive = 7
0.04 Luminal B/Her2 pos. = 4  
Her2-positive = 4
0.03
 non-pCR Luminal B/Her2-pos. = 12  
Her2-positive = 4
Luminal B/Her2 pos. = 9  
Her2-positive = 0
response markers
SUVmax1
 pCR  5 27.1 ± 17.8 0.02 8 13.1 ± 6.4 0.37
 non-pCR  9 12.1 ± 4.9 8  9.8 ± 4.2
SUVmax2
 pCR  5  1.4 ± 0.7 0.59 8  1.5 ± 0.5 0.10
 non-pCR  9  1.9 ± 1.4 8  3.4 ± 3.2
SUVmax changes
 pCR  5 92.7 ± 5.5 0.14 8 84.5 ± 11.8 0.05
 non-pCR  9 80 ± 16.2 8 64 ± 28.8
Size 1 (mm)
 pCR 10 34.3 ± 14.6 0.38 8 29.6 ± 7.1 0.74
 non-pCR 16 28.7 ± 13.3 9 36.9 ± 18.1
Size 2 (mm)
 pCR  8  9.7 ± 8.7 0.17 8 10.7 ± 6.9 0.12
 non-pCR 12 15.6 ± 9.9 5 22.6 ± 16.2
Size changes
 pCR  8 74.1 ± 20.31 0.07 8 64.8 ± 26.6 0.12
 non-pCR 12 46.8 ± 35.1 5 38.9 ± 21.2
*SuVmax 1 and 2 – maximum of the standardized uptake value before (SuVmax 1) and after (SuVmax 2) the primary systemic therapy.. Ki-67 Li – Ki-
67 labeling index.
†Fisher exact test results. otherwise: Mann-Whitney test. Significant results in bold.
‡unknown: in 1 patient from Group 1.
§unknown: in 1 patient from Group 2.
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and adjuvant trastuzumab treatment (Group 1) and 17 pa-
tients received a trastuzumab-containing, taxane-based 
PST protocol (Group 2) (Table 1). After PST, every patient 
gave consent to surgery: 25 patients (58.1%) underwent 
mastectomy and 18 (41.9%) had breast-conserving surgery 
(sector resection of the breast or quadrantectomy), with 40 
axillary block dissections (93%) and 3 sentinel lymph node 
biopsies (7%). Re-excision was not necessary.
Tumor remission and response evaluation
All 43 primary tumors were morphologically measurable at 
the time of diagnosis (both with ultrasound and CT by RE-
CIST 1.1 criteria, if applicable) (33) and metabolically active 
on the FDG-PET/CTs. FDG-PET/CT was performed to mea-
sure tumor remission in 14 patients from Group 1 and 16 
from Group 2. Results of ultrasound measurements regard-
ing local extension and its changes were available in both 
groups (20 and 13 patients in Group 1 and 2, respectively).
Favorable response to PST was observed in both groups. 
10 patients (38.5%) from Group 1 and 8 (47%) from Group 
2 showed pCR. Tumors belonging to the Her2-positive sub-
types showed pCR significantly more frequently than Lumi-
nal B/Her2-positive tumors (P = 0.043 and P = 0.029, respec-
tively). Out of the 15 Her2-positive tumors, 11 showed pCR: 
7 in Group 1 and 4 in Group 2. Of the 28 Luminal B/Her2-
positive tumors, only 7 showed pCR: 3 in Group 1 and 4 in 
Group 2 (Table 2).
In Group 1 the initial FDG uptake was significantly higher in 
pCR than in non-pCR patients. Other parameters of tumor 
metabolism, the results of morphological measurements 
(tumor size before or after PST or changes in size), and ini-
tial tumor proliferation activity (core-biopsy Ki-67 LI) were 
not significantly different between pCR and non-pCR pa-
tients (Table 2).
The accuracy of PET/CT and breast ultrasound for clinical 
discrimination of pCR-/non-pCR groups was also mea-
sured (Table 3). The ultrasound results in both groups fol-
lowed the same pattern: the number of false positive cases 
was considerably high (6 cases in Group 1 and 7 cases in 
Group 2), while PPV (62.5% in Group 1 and 41.7% in Group 
2) and specificity (25% in Group 1 and 12.5% in Group 2) 
were low. However, false negativity was also low (2 cases in 
Group 1 and 0 in Group 2).
Evaluation of tumor response by PET/CT with Method 1 
showed a higher number of false negative cases compared 
to ultrasound (7 cases in Group 1 and 5 cases in Group 2). 
However, the number of false positive cases was very small 
(0 cases in Group 1 and 1 case in Group 2); PET successfully 
detected the residual disease.
Evaluation of tumor response by PET/CT with Method 2 
had high sensitivity (77.8% in Group 1 and 87.5% in Group 
2) and high specificity (100% in Group 1 and 62.5% in 
Group 2). The number of false negative cases was low (0 
in Group 1 and 3 in Group 2) and NPV was considerably 
higher compared to Method 1 (Group 1: 71.4% vs 41.7%; 
Group 2: 83.3% vs 58.3%).
DiSCuSSion
In Her2 overexpressing breast cancer, adding trastuzumab 
to chemotherapy regimens during PST improved clinical 
outcomes and resulted in higher rates of pCR (11,34-38). In 
agreement with these reports, we showed that the pCR rate 
after PST with concomitant trastuzumab was higher (47%, 
TABLe 3. Diagnostic test evaluation for breast ultrasound and PeT/CT evaluated by Method 1 and Method 2*
ultrasound PeT/CT Method 1 PeT/CT Method 2
Group 1  
(n = 20)
Group 2 
(n = 16)
Group 2 
(n = 14)
Group2 
(n = 16)
Group 1 
(n = 14)
Group 2 
(n = 16)
Sensitivity (%)
(95% CI)
83.3
(51.6-97.4)
100
(47.9-100)
22.2
(3.5-59.9)
37.5
(9-75.3)
77.8
(40.1-96.5)
87.5
(47.4-97.9)
Specificity (%)
(95% CI)
25.0
(3.4-64.9)
12.5
(2.1-52.6)
100
(47.9-100)
87.5
(47.4-97.9)
100
(47.9-100)
62.5
(24.7-91)
Positive predictive value (%)
(95% CI)
62.5
(35.5-84.7)
41.7
(15.3-72.2)
100
(19.3-100)
75
(20.3-95.9)
100
(58.9-100)
70.0
(34.8-92.9)
Negative predictive value (%)
(95% CI)
50.0
(8.3-91.7)
100
(16.5-100)
41.7
(15.3-72.2)
58.3
(27.7-84.7)
71.4
(29.3-95.5)
83.3
(36.1-97.2)
False positive (No.) 6 7 0 1 0 3
False negative (No.) 2 0 7 5 2 1
*PeT/CT: Positron emission Tomography and Computerized Tomography; Ci – confidence interval.
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Group 2) than in the patient group that did not receive ad-
ditional trastuzumab therapy during the PST (Group 1, with 
a pCR rate of 38.5%). Therefore, we confirmed the clinical 
benefit of trastuzumab-containing PST in the daily routine; 
moreover, trastuzumab performed even better in the dai-
ly practice than it did in clinical trial conditions – the pCR 
rate in our study was 47% in the trastuzumab arm, which 
is better than the 43% achieved in the NOAH trial (11) or 
the 31.7% pCR rate in the GeparQuattro study (37). We also 
confirmed that in the case of Her2 overexpressing breast 
cancer, trastuzumab should be part of the PST, and not just 
administered adjuvantly.
While analyzing the main characteristics of the breast tu-
mors we compared the patients who achieved pCR and 
those who did not. In contrast to an earlier report (39), pCR 
and non pCR patient groups in our study did not show 
any difference in the initial Ki-67 LI. Moreover, we did not 
detect significant differences between grade 2 and 3 tu-
mors, although all patients achieving pCR in Group 2 had 
grade 3 carcinomas.
In our study, Her2-positive tumors achieved pCR more 
frequently than Luminal B/Her2-positive subtypes. This is 
in agreement with an earlier report that suggested dif-
ferent clinical behavior of these tumor subtypes (40). Lu-
minal B/Her2-positive group is a rarely investigated but 
important subgroup of Her2 overexpressing tumors, for 
which targeted therapy could be applied during the PST. 
While in the Her2-positive subtypes, pCR is predictive for 
favorable clinical outcome, in the Luminal B/Her2-posi-
tive subgroup it might not be a surrogate endpoint and 
might not be associated with improved disease-free sur-
vival (41). Until this question remains obscure, in case of 
Luminal B/Her2-positive, primarily resectable disease, 
clinical oncologists should consider choosing surgical 
treatment instead of PST as first therapeutic approach. 
Consequently, if Luminal B/Her2-positive subgroup less 
frequently achieves pCR, the indication for PST for these 
patients should only be downstaging of the disease (to 
increase the number of patients eligible for breast-con-
serving surgery) (3,42-44). This clinical approach should 
be considered until we are able to subdivide the Luminal 
B/Her2-positive subgroup to detect those patients who 
would surely achieve pCR, thus bearing the survival ben-
efit of PST. Further randomized clinical trials with a larger 
cohort are needed, and the subdivision and differentia-
tion should be based on a reliable imaging modality or 
biomarkers However, if we decide to apply different 
therapeutic protocols to different tumor subtypes, 
we risk the bias of the initial core biopsy sampling: biopsy 
results could be misguided by tumor heterogeneity and 
sampling methodology. A suitable tool to measure this 
heterogeneity and guide the biopsy sampling could be 
PET/CT (45).
Our study showed that the initial FDG-uptake of tumors 
(SUVmax1 measured before the PST) was significantly 
higher in pCR group than in non- pCR group, but only in 
Group 1. However, change in SUVmax showed no signifi-
cant difference between pCR and non-pCR patients, and 
only a slight difference was detected in Group 2. These 
findings underline the previous results (19,21), which sug-
gested that the change in SUVmax did not correlate with 
pCR in Her2 overexpressing tumors. This is contrary to the 
findings in triple negative breast cancers, when changes in 
the FDG-uptake correlated well with the achieved patho-
logical remission rate (46).
A limited number of studies are available on the appli-
cation of FDG-PET/CT in Her2 overexpressing breast car-
cinomas (15-21). The rationale behind our study was the 
emerging role of hybrid imaging technologies for response 
evaluation during PST, but there is a lack of experience in 
this particular patient group, especially when treated with 
targeted anti-Her2 therapy. The suitability of FDG-PET/CT 
has already been proven in breast cancer (12-14), but its 
efficacy depends on several tumor-properties, for instance 
histological tumor type (invasive ductal carcinomas are 
better candidates for PET/CT examinations than invasive 
lobular cancers) or proliferation rate (high Ki-67 LI is favor-
able in this respect) (47-49). FDG-uptake is also influenced 
by biological subtypes; Her2-positive carcinomas (and tri-
ple negative, especially basal like tumors) (24) show higher 
FDG-uptake than hormone receptor positive ones (50,51).
The accuracy of response evaluation with FDG-PET/CT in 
Her2 overexpressing breast carcinomas is contested. Small 
animal PET had a high positive predictive value for evalu-
ation of tumor response to trastuzumab therapy in pre-
clinical settings (15). However, in clinical research PET/CT 
was less accurate, and a possible inflammatory response 
induced by trastuzumab was assumed, which could have 
resulted in false positivity during PET imaging (16). Trastu-
zumab also seemed to have an effect on cellular glucose 
metabolism with a possible reduction of glucose uptake 
and consumption and FDG-incorporation (17). New trac-
ers, especially radiopharmaceutically labeled (pl. 89Zr) tras-
tuzumab or its fragments, are good candidates for PET/
CT imaging during anti-Her2 therapy (18) and could pos-
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sibly resolve the above mentioned bias of FDG-based PET/
CT imaging. Nevertheless, PET/CT imaging proved to be 
highly predictive for pCR by Groheux et al (19), Hatt et al 
(20), and Humbert et al (21), even after one or two admin-
istered cycles of PST. Apart from these favorable results 
and the expanding application of FDG-PET/CT in daily on-
cological practice, our results underline the importance of 
a novel, combined metabolism and morphology-based 
response evaluation system in Her2 overexpressing breast 
carcinomas for CR.
In our study, the conventionally and routinely applied 
breast ultrasound poorly identified residual tumors and ap-
peared to be inferior for response evaluation after the PST 
than PET/CT imaging – evaluated by both methods. Nei-
ther the breast ultrasound-based nor the PERCIST-based 
definitions of CR (PET/CT with Method 1) were accurate 
enough to predict pCR. The novel, combined definition 
(PET/CT with Method 2) – based on PERCIST and RECIST 
criteria – accurately separated pCR and non-pCR patients, 
in both treatment groups. These combined criteria more 
accurately confirmed residual disease and more specifi-
cally identified pCR. These results support the hypothesis 
based on our earlier results: RECIST criteria should be in-
cluded in the therapeutic response evaluation criteria of 
breast cancers after PST (52).
The main limitation of our study was the relatively low 
number of patients, due to the limited availability of neo-
adjuvant trastuzumab treatment in Hungary at the time of 
the study. The number of patients prevented further differ-
entiation of cases to analyze the deeper molecular mecha-
nism involved in PET/CT imaging to explore differences in 
the FDG-consumption between Her2-positive and Luminal 
B/Her2-positive subtypes. However, Groheux and Humbert 
did not find significant differences between the FDG-con-
sumption in these two patient groups (19,21), which is why 
we did not consider it necessary to address this issue in the 
present study. In addition, CT response evaluation plays an 
important role in our study, although it has limited accura-
cy in breast tissue. However, in our study all tumors evalu-
ated by RECIST criteria were confirmed to be morphologi-
cally measurable at the time of the initial PET/CT, justifying 
the application of this method.
In summary, in Hungary PST treatments with trastuzumab 
are now part of the daily routine. The benefit of these regi-
mens is visible in Her2 overexpressing tumors compared 
with previous regimens without trastuzumab that used 
pCR as primary endpoint. However, our findings suggest a 
possible association between biological subtypes and clin-
ical outcome of PST. In the Luminal B/Her2-positive sub-
group pCR was less frequent than in the Her2-positive sub-
type. This subgroup might need further subdivision using 
clinical biomarkers to identify those Luminal B/Her2 posi-
tive patients who would achieve pCR. In this patient group, 
PST should only be considered for downstaging the dis-
ease to reach operability or to support a breast-conserving 
surgical approach.
In conclusion, response evaluation after PST in Her2 over-
expressing tumors with a metabolism based imaging 
technique (PET/CT) outperformed the applied conven-
tional imaging methods (breast ultrasound). Moreover, 
our novel PET/CT response criteria, which comprise the 
PERCIST and RECIST criteria for defining CR, accurately 
separated pCR and non-pCR patients and were easy to 
apply in the daily practice.
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